Angel CoFund

"this investment will allow us to move the company into the next phase with a system that has a place in a clinical workflow and more exciting functionality to come as soon as clinical data collection can re commence"

"Our vision is for any size company, in any sector, to have access to business-critical HR data. We aim to help all clients navigate some of the most difficult employment issues that they are facing today. Our experience has shown us that companies are ready and willing to address HR issues within their businesses, they just need to be armed with the insights to do it. Our platform can be instantly transformative to clients, as well as delivering material cost savings to businesses of all sizes. We are delighted to have such a strong, experienced and engaged syndicate of angel investors, as well as the Angel CoFund on board to help us capitalise on the huge growth we are seeing."

"For decades, pest management has been held back by laborious, error-prone manual monitoring. With our technology it is finally possible to change this and help industries around the world to make a step change from reactive to proactive management of pests. This will save billions and massively reduce the amount of pesticide used globally. We’re delighted to have strong support from a wide group of investors who share our vision. This funding will allow us to scale up our commercial operations and continue to address the £320bn global problem of insect pests."

"Our work in the US and the success of the trials we have run to date have demonstrated the potential of our technology and encouraged us to pursue other applications. With this financing and the backing of our investors we can accelerate our mission of delivering effective and non-invasive solutions for some of the most common and debilitating medical conditions."

"We are delighted to continue working with Par Equity who have been very supportive of our company and our vision. This investment will enable us to continue to develop and commercialise our cutting-edge technology that addresses a major unmet need in the development of novel therapies that can significantly reduce costs of care and improve patient outcomes for millions of people worldwide."

"Many years ago we set out to build a platform that would empower programmatic digital trading with levels of creativity not otherwise seen, while baking in as automated features, optimum solutions for real-time fraud management. It has taken a long time but we are truly excited to now be in market with what many say is a game-changing offering. Being able to close a round at this particular time is a testament to that technology offering and the belief shown by existing and new investors alike. I am also thrilled to welcome the Angel CoFund to the business."

"DPL’s unique platform has the ability to transform marketing and customer engagement for countless businesses, and offers a considerably enhanced experience for end consumers. We are very pleased to be supporting a highly experienced team bringing a truly game changing product to market with this funding round, and look forward seeing clients really tangibly benefit from the team’s insights."

"This latest funding further validates our computational design-led focus that has enabled rapid progress in building our pipeline of novel antibiotic programmes."

"Additive Manufacturing is currently one of the fastest growing, disruptive technology spaces, providing manufacturers with the ability to produce high value components that would have been impossible even ten years ago. We are excited to be developing our new product in such a high-potential market, and look forward to driving its rapid growth as we prepare to launch in the coming years."

"autologyx has maintained an excellent track record since we first invested in the team, and they’ve delivered some first class results for customers. Their growth demonstrates a strong market demand for solutions that can help businesses automate everyday processes and increase efficiency. We are pleased to be part of this round supporting autologyx’s continued success."

"Our mission is to make it easier for consumers to connect with service providers in regulated industries like Financial Services. Our clients are using Nivo to deliver simpler mobile experiences, which reduce effort and empower customers. This means everyone saves time, costs go down and satisfaction goes up."

"We are delighted to receive this latest wave of funding, it will enable us to continue to lead the way in developing non-invasive neuro-stimulation technology and will propel our work to a whole new level,"

"We are really supportive of the Form3 mission to open access to payment systems. This is much needed around the world and helps companies like N26 scale faster globally and build products their customers love to use"